W
ITH A SIGNIFICANT ORgan shortage in the United States and with minimal expansions of the deceased donor pool in recent decades, many patients with end-stage renal disease are turning to live donor kidney transplantation to improve survival and quality of life. [1] [2] [3] [4] [5] Although many healthy adults are eager and willing to accept the risk of donor nephrectomy to help their loved ones, the responsibility lies within the medical community to quantify these risks as best as possible and to make this information available to those considering donation.
Evidence to date suggests that live kidney donation is safe. 3, [6] [7] [8] [9] [10] [11] [12] [13] [14] In fact, some studies show that live donors have better outcomes than their population counterparts. 1, 3 But inferences have thus far been limited by lack of generalizability, restrictive sample size, and inappropriate comparison groups. Most studies that have evaluated live donor outcomes have been conducted at single academic centers with carefully selected, primarily white individuals who receive close follow-up and are often involved in funded research studies. Furthermore, although some single centers have studied as many as 3700 donors, 3 the event rate for long-term death in live donors is so low that the power to detect differences in outcomes is limited with these sample sizes. Finally, comparison groups for long-term outcomes have been limited to published population-based life tables or heavily confounded reference populations and as such lack the ability to select healthy controls in a manner comparable with the screening process for kidney donors. The goal of our study was to extend previous studies of live donor outcomes to a large generalizable cohort of all live kidney donors in the United States during a 15-year period, to study national trends in live kidney donor selection and outcome, to estimate shortterm operative risk in various strata of live donors, and to improve the long-Context More than 6000 healthy US individuals every year undergo nephrectomy for the purposes of live donation; however, safety remains in question because longitudinal outcome studies have occurred at single centers with limited generalizability.
Objectives To study national trends in live kidney donor selection and outcome, to estimate short-term operative risk in various strata of live donors, and to compare longterm death rates with a matched cohort of nondonors who are as similar to the donor cohort as possible and as free as possible from contraindications to live donation.
Design, Setting, and Participants Live donors were drawn from a mandated national registry of 80 347 live kidney donors in the United States between April 1, 1994, and March 31, 2009 . Median (interquartile range) follow-up was 6.3 (3.2-9.8) years. A matched cohort was drawn from 9364 participants of the third National Health and Nutrition Examination Survey (NHANES III) after excluding those with contraindications to kidney donation.
Main Outcome Measures Surgical mortality and long-term survival.
Results There were 25 deaths within 90 days of live kidney donation during the study period. Surgical mortality from live kidney donation was 3.1 per 10 000 donors (95% confidence interval [CI], 2.0-4.6) and did not change during the last 15 years despite differences in practice and selection. Surgical mortality was higher in men than in women (5.1 vs 1.7 per 10 000 donors; risk ratio [RR], 3.0; 95% CI, 1.3-6.9; P=.007), in black vs white and Hispanic individuals (7.6 vs 2.6 and 2.0 per 10 000 donors; RR, 3.1; 95% CI, 1.3-7.1; P = .01), and in donors with hypertension vs without hypertension (36.7 vs 1.3 per 10 000 donors; RR, 27.4; 95% CI, 5.0-149.5; PϽ.001). However, long-term risk of death was no higher for live donors than for age-and comorbidity-matched NHANES III participants for all patients and also stratified by age, sex, and race.
Conclusion Among a cohort of live kidney donors compared with a healthy matched cohort, the mortality rate was not significantly increased after a median of 6.3 years. Additional exclusion factors included answering "yes" to any of the questions listed in the eTable (available at http://www.jama.com). Finally, NHANES III participants who were missing information on kidney disease, diabetes, heart disease, or hypertension could not serve as part of a comparison cohort and were thus excluded (n=1228). A total of 9364 NHANES III participants remained who were without contraindications to live donation; 1 matched control for each live kidney donor was selected from this remaining NHANES III population with replacement, as fully delineated in the eMethods (available at http://www.jama .com).
Statistical Analysis
Mortality estimates were obtained by Kaplan-Meier curve methods, with administrative censoring at the time of linkage to the Social Security Death Master File. For live donors, time at risk was accrued from the date of donation. For NHANES III controls, time at risk was accrued from the date of enrollment into the study. Early postsurgical (3-month and 12-month) death rates were calculated per 10 000 donors with 95% confidence intervals (CIs) derived using Poisson exact intervals. Differences in early postsurgical deaths across donor characteristics were analyzed by using 2 tests of independence. Associations between donor characteristics and long-term death (all deaths including early deaths) were analyzed using nested Cox proportional hazards regression models.
Long-term death rates between live kidney donors and the matched cohort were compared using log-rank tests. Based on the number of patients for whom we had 10-year follow-up and a 10-year survival of 97%, we had 80% power to detect a difference of 1%; in other words, if live donor survival at 10 years was 96% or lower and matched cohort survival was 97%, we would anticipate having the power to detect this difference. All analyses were performed by using multiprocessor Stata version 11.0/MP for Linux (StataCorp, College Station, Texas), with ␣ = .05. When applicable, all hypothesis tests were 2-sided.
RESULTS

Donor Demographics
There was a significant increase in live donor kidney transplants in the United States during the last 15 years (from 3009 in 1994 to 5968 in 2008). Donor age changed considerably over time, with 13.9% of donors older than 50 years in 1994 compared with 22.8% in 2008. A total of 58 683 live kidney donors (73.1%) were white, 10 505 (13.1%) were black, and 9846 (12.3%) were Hispanic (TABLE 1) . Educational backgrounds varied, with 38.4% of live kidney donors educated at grade school or high school level, 28.0% with some college, and 33.6% with a bachelor's degree or postcollege. Of donors where body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) information was available (after 2003), 22.6% were obese (BMI Ն30). Very few individuals (1.8%) were categorized as having hypertension in the same era.
Early Postsurgical Death
In general, the risk of death in the first 90 days following live donor nephrectomy was 3.1 per 10 000 donors in the first 90 days (95% CI, 2.0-4.6) (TABLE 2). Although more conservative than the commonly used 30-day perioperative mortality metric, death in the first 90 days seemed a good measure of surgical mortality, because this rate greatly exceeded the risk of death in the first 90 days for the NHANES III matched cohort (0.4 per 10 000 donors; 95% CI, 0.1-1.1; P Ͻ .001) compared with live donors. By 1 year following nephrectomy, risk of death in the matched cohort was similar (4.6 per 10 000 donors; 95% CI, 3.2-6.3; vs 6.5 per 10 000 donors; 95% CI, 4.8-8.5; P = .11) to the live donor cohort, likely representing deaths attributable to com o r b i d i t y r a t h e r t h a n s u r g i c a l mortality.
Surgical mortality did not change during the 15-year period, despite differences in surgical practice and donor selection (Table 2 ). Men had a statistically significantly higher surgical mortality than women did (5.1 per 10 000 donors; 95% CI, 3.0-8.2; vs 1.7 per 10 000 donors; 95% CI, 0.7-3.4; risk ratio [RR], 3.0; 95% CI, 1.3-6.9, P = .007), as did black individuals vs white and Hispanic individuals (7.6 per 10 000 donors; 95% CI, 3.3-15.0; vs 2.6 per 10 000 donors; 95% CI, 1.4-4.2; and 2.0 per 10 000 donors; 95% CI, 0.2-7.3; RR, 3.1; 95% CI, 1.3-7.1; P=.01 vs nonblack individuals). Donors with hypertension also had a statistically significantly higher surgical mortality than did donors without hypertension (36.7 per 10 000 donors; 95% CI, 4.4-132.6; vs 1.3 per 10 000 donors; 95% CI, 0.4-3.4; RR, 27.4; 95% CI, 5.0-149.5; P Ͻ.001), although this was based on only 2 deaths among 545 donors with hypertension; therefore, as indicated by the wide CI, the magnitude of the excess surgical risk remains quite uncertain. No statistically significant difference in surgical mortality was observed by age, smoking status, BMI, or systolic blood pressure (SBP).
Long-term Donor Survival
Similar associations were observed when studying long-term mortality after live kidney donation as were shown in postsurgical death rates. When analyzing the entire cohort of live donors, individuals aged 50 to 59 years (hazard ratio [HR], 3.3; 95% CI, 2.6-4.1; unadjusted 3.5% 12-year mortality for this subgroup vs 1.3% 12-year mortality for those adults younger than 40 years), aged 60 years or older (HR, 9.4; 95% CI, 7.3-12.1; unadjusted 9.4% 12-year mortality for this subgroup), male sex (HR, 1.7; 95% CI, 1.5-2.0; unadjusted 2.7% 12-year mortality for men vs 1.9% 12-year mortality for women), and black race (HR, 1.3; 95% CI, 1.0-1.6; unadjusted 2.8% 12-year mortality for black individuals vs 1.7% 12-year mortality for white individuals) were associated with higher rates of long-term death (model 1 in TABLE 3). These associations were also observed in the cohort of donors between 2000 and 2009, where information about SBP was also available (model 2 in Table 3 ). In this cohort, SBP of 140 mm Hg or higher was also associated with a higher rate of death (HR, 1.7; 95% CI, 1.1-2.9; unadjusted 4.0% 9-year mortality vs 1.4% 9-year mortality for SBP of Ͻ120 mm Hg) (model 2 in Table 3 ).
Missing covariate data resulted in a cohort limited to donors between 2004 and 2009 when studying the effect of smoking and hypertension (model 3 in Table 3 ). This cohort was one-fourth the size of the full cohort, with about one-third of the follow-up time (median [interquartile range], 2.1 [1.0-3.1] years; vs 6.3 [3.2-9.8] years for the full cohort), and many of the associations observed in the larger cohorts with longer follow-up were not detected in this model. In fact, the only statistically significant associations were SBP of 140 mm Hg or higher (HR, 3.3; 95% CI, 1.1-9.7; unadjusted 4% 9-year mortality vs 1% 9-year mortality for SBP of Ͻ120 mm Hg) and smoking (HR, 5.3; 95% CI, 2.6-10.8; unadjusted 1.0% 4-year mortality vs 0.7% 4-year mortality for nonsmokers), while hypertension was not associated with increased risk of death (HR, 0.9; 95% CI, 0.1-6.6; unadjusted 0.7% 3-year mortality vs 0.5% 3-year mortality for those donors without hypertension).
Matched NHANES III Cohort
Although 90-day death rates were higher for live kidney donors (Table 2) , long-term mortality was similar or lower for live kidney donors than for the matched NHANES III cohort throughout the 12-year period of follow-up (5-year follow-up: 0.4% vs 0.9% and 12-year follow-up: 1.5% vs 2.9%; P Ͻ .001 by log-rank test) (FIGURE 1). 
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©2010 American Medical Association. All rights reserved. Similar patterns were observed when comparing live kidney donors with matched controls stratified by age (FIGURE 2), sex (FIGURE 3), and race ( Figure 3 ) (P Ͻ .001 for all comparisons by log-rank test). 15 and approximately 260 per 10 000 cases f o r n o n d o n o r n e p h r e c t o m y . 1 6 Although the proportion of donors older than 50 years nearly doubled, the death rate did not change over time. Similarly, although more than 20% of live donors were obese (BMI Ն30), surgical mortality was not associated with obesity. Although it is possible that surgical mortality was higher for older adults, this difference was also not statistically detectable. Surgical mortality was demonstrably higher for men (RR, 3.0), black individuals (RR, 3.1), and those reported to have hypertension (RR, 27.4), consistent with higher rates of death after other surgical procedures for these subgroups. [17] [18] [19] [20] [21] These factors were also associated with higher risk of longterm death, consistent with known population factors associated with The strength of our study lies in its generalizability, sample size, and choice of comparison group. This is the first longitudinal survival study to our knowledge that draws from the entire population of live US donors during a 15-year period. The use of a complete national population is critical, as most single-center studies to date have involved white donors without hypertension from large-volume transplant centers. For example, the largest longitudinal study of donors to date (3700 live donors at the University of Minnesota), although important and informative, is limited to a population that is nearly 100% white. 3 However, we have shown that 26% of US donors are nonwhite and outcomes differ by race/ ethnicity, with higher surgical and longterm mortality in black individuals. With more than 10 000 black individuals in our study, we were also able to compare survival of these donors with their NHANES III controls; this comparison has not been possible in previous studies.
COMMENT
The large sample size of more than 80 000 live donors allows for more robust inferences about surgical mortality, which is a rare event (3.1 per 10 000 cases overall), and for comparison of death rates by various strata, including age, sex, race/ethnicity, BMI, SBP, and smoking. This is particularly relevant in terms of donor counseling, because risk awareness is the essence of informed consent when a healthy person embarks on a major operation. Previous surgical mortality estimates have been based mostly on self-report and literature review, with the risk of reporting bias, recall bias, and publication bias. Estimates currently quoted to candidate donors range from 0.03% based on a self-reported survey of members of a professional society conducted in 1992 8 to 0.06% based on a study of 8200 live donors drawn from the literature and a self-reported survey conducted in 1987. 22 Surgical mortality in the recent era has not been estimated in general or for any stratified populations. The 15-year period included in our study is inclusive of the transition from the predominance of the open nephrectomy to the laparoscopic nephrectomy. 23, 24 Although not statistically significant, it is entirely possible that the increase in surgical mortality between 1994-1997 Abbreviations: CI, confidence interval; IQR, interquartile range; NA, not applicable; SBP, systolic blood pressure. a Number of observations (changes because of missing data; see Table 1 for covariate availability). Hazard ratios (95% CIs) were estimated from Cox proportional hazards regression models. Model 1 includes demographics only (age, sex, race/ethnicity); model 2 includes demographics and SBP; and model 3 includes demographics, SBP, smoking, and hypertension. However, clearly live donors are very carefully selected and an appropriate comparison group should be selected in a similar manner. In applying our exclusion criteria, which were based on standard live donor candidate workup 4 as best ascertained by NHANES III data, more than half of the NHANES III cohort were found to be ineligible for live donation, illustrating the bias that is inherent in population-based comparison groups. Our matched cohort was thus carefully constructed to represent (within the limitations of the data) potential candidates for live donation and oversampled to represent the demographic distribution of the live donor cohort. Despite these efforts, unmeasured confounding still likely explains the lower observed survival among the matched cohort, given that candidate live donors are very carefully screened by multidisciplinary teams and significant laboratory and radiographic testing, while we were only able to exclude a proportion of the NHANES III controls based on approximately 30 screening questions.
Our study is limited by availability of data, duration of follow-up, and statistical artifacts resulting from an oversampled matched cohort. Of the 80 347 donors registered by national mandate through UNOS, all had information about age, sex, race/ethnicity, and vital status throughout the study period. However, more granular information about education, BMI, SBP, hypertension, and smoking was only available in the later periods. As a result, our ability to estimate early surgical mortality stratified by these factors was limited to a smaller (yet still very large and nationally representative) subset of donors (n=22 745-47 695). Furthermore, our ability to make inferences about the ef- fects of SBP, hypertension, or smoking on long-term survival was limited by shorter follow-up (maximum followup, 4.3-9.3 years vs 15.1 years for those donors with only age, sex, and race/ ethnicity information).
Although NHANES III is a large, representative, and commonly studied population of potential comparison patients, this cohort was one-eighth the size of the live donor cohort after appropriate exclusions. As a result, in generating a matched cohort based on these patients, we had to sample with replacement (some patients were used more than once in the matched cohort). Although this accounted for confounding by making the matched cohort similar in demographics to the live donor cohort, the oversampling caused an artificially larger sample size for the purposes of standard error estimates.
Of all statistical analyses performed in our study, the only one affected was the statistical comparison of the live donor survival with the matched cohort survival, where we found that live donors had a statistically significantly better survival than their NHANES III counterparts. Although it is unlikely that this substantial difference was driven by the artificial increase in sample size, we can still safely conclude that live donors did not have statistically significantly worse survival than their NHANES III counterparts.
We have shown that live kidney donation is safe and free from significant long-term excess mortality. Although perioperative mortality is low (3.1 of 10 000 cases), some subgroups seem to be at higher risk and individuals from these demographic groups should be counseled accordingly. Importantly, although selection criteria have changed over time and more adults older than 50 years are donating, we found no evidence that these adults are at higher risk of surgical mortality and no evidence that surgical mortality is changing over time. This suggests that current screening practices, even in older age groups, still result in a well-selected group of healthy adults.
Regardless of what physiologic changes might occur in a healthy adult after kidney donation, our findings of similar long-term survival between donors and healthy comparison patients suggest that these physiologic changes do not result in premature death. Although additional studies are clearly needed to better understand the physiologic changes after kidney donation, the current practice of live kidney donation should continue to be consid- 
